Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
27/10/2026 13:57
BRIEF-SynAct Pharma Signs First Commercial Partnership For Resomelagon Oct 27 (Reuters) - SynAct Pharma AB SYNACT.ST:
SYNACT PHARMA SIGNS FIRST COMMERCIAL PARTNERSHIP FOR RESOMELAGON WITH LEADING BRAZILIAN PHARMACEUTICAL COMPANY
COLLABORATION BUILDS ON SYNACT'S ONGOING RESOVIR-2 CLINICAL DEVELOPMENT PROGRAM
RESULTS FROM PART 1 EXPECTED IN 2026 PENDING FEEDBACK FROM REGULATORY AUTHORITIES
TOPLINE RESULTS OF FULL STUDY EXPECTED DURING Q2 OF 2027
AGREEMENT INCLUDES 50/50 PROFIT-SHARING AND SALES MILESTONES LINKED TO $200 MILLION NET SALES
AGREEMENT INCLUDES 50/50 SHARING OF DEVELOPMENT COSTS FOR REGULATORY APPROVAL IN BRAZIL
Source text: ID:nMFN4q4Qq3
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development